This database contains 91 studies, archived under the term: "and"
Click here to filter this large number of results.
Evaluating proFamilies-dementia: adopting photovoice to capture clinical significance
Dementia is a challenging chronic illness that affects the patients and their families. Families often perform a full-time, specialised role, which requires expert knowledge and skills. This paper describes the evaluation of proFamilies-dementia (a programme developed to support families that care for a relative with dementia) using an innovative participatory methodology: photovoice, a qualitative method […]
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n – 3 fatty acid supplementation in patients with Alzheimer’s disease: the OmegAD study
Faxén-Irving, Gerd,
Freund-Levi, Yvonne,
Eriksdotter-Jönhagen, Maria,
Basun, Hans,
Hjorth, Erik,
Palmblad, Jan,
Vedin, Inger,
Cederholm, Tommy,
Wahlund, Lars-Olof
Transthyretin (TTR) binds amyloid-β (Aβ) and may reduce brain Aβ, a pathological feature in Alzheimer’s disease (AD). N – 3 fatty acids (FA), docosahexaenoic (DHA), and eicosapentaenoic acid (EPA) may increase TTR transcription in rat hippocampus. We studied effects of n – 3 FA supplementation on TTR-levels in patients with AD. Outpatients were randomized to […]
“Learning to become a family caregiver” efficacy of an intervention program for caregivers following diagnosis of dementia in a relative
Ducharme, F. C.,
Levesque, L. L.,
Lachance, L. M.,
Kergoat, M.-J.,
Legault, A. J.,
Beaudet, L. M.,
Zarit, S. H.
Purpose: The purpose of this experimental study was to test the efficacy of a psychoeducational individual program conceived to facilitate transition to the caregiver role following diagnosis of Alzheimer disease in a relative.; Design and Methods: Caregivers were recruited in memory clinics and randomized to an experimental group (n = 62) or a control group […]
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Dodel, Richard,
Rominger, Axel,
Bartenstein, Peter,
Barkhof, Frederik,
Blennow, Kaj,
Förster, Stefan,
Winter, Yaroslav,
Bach, Jan-Philipp,
Popp, Julius,
Alferink, Judith,
Wiltfang, Jens,
Buerger, Katharina,
Otto, Markus,
Antuono, Piero,
Jacoby, Michael,
Richter, Ralph,
Stevens, James,
Melamed, Isaac,
Goldstein, Jerome,
Haag, Stefan,
Wietek, Stefan,
Farlow, Martin,
Jessen, Frank
Background: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer’s disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.; Methods: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer’s […]
Neuromidin in mixed vascular and Alzheimer’s dementia
The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer’s dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of […]